Back on-line after unexpected 18 day shut down due to Covid-19

Back on-line after unexpected 18 day shut down due to Covid-19 Image

Raybow is happy to announce that on Monday March 2nd we restored our Chinese R&D and manufacturing sites to full capacity as all of our employees we able to return, healthy and safe from their various quarantine locations. The Raybow team is fully committed to catch up quickly from the unexpected 18 day shut down due to Covid-19 isolation. Raybow is now running our 5 facilities 24/7 to achieve this aim.

No medicines were delayed as contingency stock has buffered the 18-day delay. Our operations in USA and Europe were not affected by Covid-19 at the time of this writing. We continue to monitor the situation globally.

Other Raybow News & Papers

Raybow Attends Bio-Europe Digital - Oct. 26th thru 29th, 2020

BIO-Europe® Digital 2020, the largest life science partnering event in Europe, runs October 26th-29th. This event is being held digitally and Raybow is there!

Green Chemistry in the development and manufacturing of pharmaceuticals

First of all, Green Chemistry is “the development of chemical products and processes to reduce or eliminate the use and generation of hazardous substances” and “is intended to apply to the development and full lifecycle of a chemical product” i.e. development, manufacturing, application and disposal.

Back on-line after unexpected 18 day shut down due to Covid-19

Raybow is happy to announce that on Monday March 2nd we restored our Chinese R&D and manufacturing sites to full capacity.

Raybow Expands CDMO Business to U.S. with Acquisition of PharmAgra Labs

Raybow Pharmaceutical, a global pharmaceutical chemistry services provider, has acquired US-based PharmAgra Labs.